vVardis sets NYSE IPO terms at $21-$24, seeking up to $229M

Swiss dental health firm vVardis is seeking up to $229 million in a NYSE IPO, offering 9.5 million shares at $21-$24 under ticker VVVV, with Goldman Sachs and J.P. Morgan leading. Its peptide-based Curodont products treat early-stage cavities and help restore tooth enamel.

Detected & updated continuously · Source: Nebula